From the Guidelines
Zepbound (tirzepatide) is not typically recommended for individuals with a BMI of 28 alone, as it is FDA-approved for chronic weight management in adults with a BMI of 30 or greater, or adults with a BMI of 27 or greater who also have at least one weight-related condition. According to a recent review published in JAMA 1, tirzepatide has been shown to be effective in weight loss, with a mean weight loss of 20.9% for 15 mg of tirzepatide at 72-week follow-up. However, for someone with a BMI of 28 without weight-related conditions, Zepbound would not be indicated according to current guidelines. Some key points to consider:
- Zepbound works by mimicking hormones called GLP-1 and GIP that regulate appetite and food intake, as described in the JAMA review 1.
- Before considering medication, lifestyle modifications including diet changes and increased physical activity should be attempted.
- If weight-related health conditions are present, a healthcare provider might consider prescribing Zepbound, starting at a lower dose and gradually increasing as tolerated.
- Side effects can include nausea, diarrhea, vomiting, and constipation, and should be discussed with a healthcare provider. It is essential to consult with a healthcare provider for personalized advice regarding weight management options, as they can assess individual needs and health status to determine the best course of treatment.
From the Research
Zepbound for BMI 28
- Zepbound, also known as tirzepatide, is a medication that has been shown to be effective for weight loss in individuals with obesity 2.
- The medication works by functioning as a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, which can help reduce body weight and improve glycemic control 2.
- Studies have demonstrated that tirzepatide can produce significant weight loss, with some trials showing superior efficacy compared to previously approved medications for obesity 2.
- However, it is essential to note that tirzepatide is not yet approved as an anti-obesity medication, and more research is needed to fully understand its effects on weight loss and overall health 2.
- For individuals with a BMI of 28, lifestyle modifications such as a reduced-calorie diet, increased physical activity, and behavior therapy are recommended as the first-line treatment for weight loss 3, 4, 5.
- A weight loss goal of 5-10% of initial body weight is considered a realistic and achievable target, and can be maintained through ongoing lifestyle modifications and support 3, 4, 5.